On Thursday, Shares of Antares Pharma Inc. (NASDAQ:ATRS), dropped -5.04% to $2.45.
Antares Pharma, declared that Eamonn P. Hobbs, President and Chief Executive Officer, will present at the Deutsche Bank Securities, Inc. 40th Annual Health Care Conference on Wednesday May 6, 2015 at 2:10 pm Eastern Time.
Antares Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide.
Shares of Agnico Eagle Mines Limited (NYSE:AEM), declined -5.02% to $30.30, during its last trading session.
Agnico Eagle Mines, stated quarterly net income of $28.7 million, or net income of $0.13 per share for the first quarter of 2015. This result comprises a non-cash foreign currency translation loss on deferred tax liabilities of $23.3 million ($0.11 per share), various mark-to-market and other adjustment gains of $22.7 million ($0.11 per share), unrealized losses on financial instruments of $13.6 million ($0.06 per share), non-cash foreign currency translation gains of $11.7 million ($0.05 per share), non-cash stock option expense of $7.8 million ($0.04 per share) and non-recurring gains of $7.6 million ($0.03). Not taking into account these items would result in adjusted net income of $31.4 million ($0.15 per share) for the first quarter of 2015. In the first quarter of 2014, the Company stated net income of $97.1 million or net income of $0.56 per share.
First quarter 2015 cash offered by operating activities was $143.5 million ($176.8 million before changes in non-cash components of working capital). This compares to cash offered by operating activities of $250.4 million in the first quarter of 2014 ($207.2 million before changes in non-cash components of working capital). The decrease in cash offered by operating activities before changes in working capital during the current period was largely due to lower realized gold and silver prices (down 8% and 17% respectively, period over period) and timing of sales which resulted in lower sales volumes relative to the ounces produced during the quarter.
Agnico Eagle Mines Limited engages in the exploration, development, and production of mineral properties. It primarily explores for gold, in addition to for silver, copper, zinc, and lead.
At the end of Thursday’s trade, Shares of Infinera Corporation (NASDAQ:INFN), dwindled -5% to $18.80.
Infinera Corporation, and Midcontinent Communications® (Midcontinent) declared that Midcontinent has deployed the Infinera DTN-X packet optical transport networking platform in its Upper Midwest service area of the United States to deliver cable television, high-speed Internet and telecom services to its customers.
Midcontinent is one of the nation’s largest independent telecommunications companies, with more than 300,000 residential and business customers in Minnesota, North Dakota, South Dakota and Wisconsin. Midcontinent operates one of the largest and most resilient optical networks in the region, a 7,800 fiber-mile network delivering services to urban and rural areas.
As demand for triple play network services enhances, Midcontinent has practiced rapid enhances in customer traffic and anticipates demand to continue to grow. The Infinera DTN-X platform enables Midcontinent to deliver capacity with 100 gigabit per second (Gb/s) coherent transmission recently using 500 Gb/s super-channels, with a forward-scale design to support in-service migration to terabit super-channels in the future. The high-capacity super-channels are enabled by 500 Gb/s photonic integrated circuits (PICs) developed and fabricated by Infinera — the only supplier delivering 500 Gb/s of transmission capacity from a single line card recently. PICs enable the DTN-X platform to integrate dense wavelength division multiplexing super-channel transmission with 5 Tb/s of non-blocking optical transport network switching recently, and 12 Tb/s in the future. The result is seamless scaling for Midcontinent as traffic requirements grow in the future.
Infinera Corporation provides optical transport networking equipment, software, and services for telecommunications service providers, Internet content providers, cable operators, wholesale and enterprise carriers, research and education institutions, and government entities worldwide.
Finally, Geron Corporation (NASDAQ:GERN), ended its last trade with -4.99% loss, and closed at $3.62.
Geron Corporation, stated financial results and recent events for the first quarter ended March 31, 2015.
First Quarter 2015 Results
For the first quarter of 2015, the company stated operating revenues of $537,000 and operating expenses of $10.0 million contrast to $474,000 and $9.2 million, respectively, for the comparable 2014 period. Operating expenses in the first quarter of 2015 comprised of restructuring charges of $406,000. Net loss for the first quarter of 2015 was $9.3 million, or $0.06 per share, contrast to $8.4 million, or $0.06 per share, for the comparable 2014 period. The company ended the first quarter of 2015 with $163.8 million in cash and investments.
Revenues for the first quarter of 2015 and 2014 comprised of royalty and license fee revenues under various agreements. Interest and other income for the first quarter of 2015 was $149,000 contrast to $83,000 for the comparable 2014 period. The enhance in interest and other income in 2015 contrast to 2014 was due to higher cash and investment balances in 2015.
Research and development expenses for the first quarter of 2015 were $5.0 million contrast to $5.2 million for the comparable 2014 period. The decrease in research and development expenses was primarily the net result of lower manufacturing costs for imetelstat drug product, partially offset by raised costs for the development of imetelstat for hematologic myeloid malignancies in partnership with Janssen Biotech, Inc. (Janssen). The company anticipates research and development expenses to enhance during the remainder of the year as the development of imetelstat continues in partnership with Janssen.
General and administrative expenses for the first quarter of 2015 were $4.6 million contrast to $4.0 million for the comparable 2014 period. The enhance in general and administrative expenses was primarily the result of higher non-cash stock-based compensation expense, raised legal fees for the defense against the securities class action and derivative lawsuits filed against the company and higher consulting costs in connection with business development activities to identify potential new product candidates.
Geron Corporation, a clinical stage biopharmaceutical company, focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has partnership and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, counting hematologic myeloid malignancies and other human therapeutic uses.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.